TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02007070

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous infusion
Study: NCT04237792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan
Study: NCT03467113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZX008 0.2 to 0.8 mg/kg/day
Description: ZX008 drug is an oral aqueous solution of fenfluramine hydrochloride. The product is sugar free.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol
Study: NCT04237792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine low, middle and high doses are provided as an intravenous bolus loading dose followed by an intravenous maintenance dose infusion throughout the MRI scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: propofol IV administration will be given if needed to maintain sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: propofol IV administration will be given if needed to maintain sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: propofol IV administration will be given if needed to maintain sedation
Study: NCT02520336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder
Study: NCT02330900

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Study group
Description: Exposure to cell phone interference of the ICD
Study: NCT00114452

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Provacel
Description: ex vivo cultured adult mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Provacel
Description: ex vivo cultured adult mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Provacel
Description: ex vivo cultured adult mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Provacel
Description: ex vivo cultured adult mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03070548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: 1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
Study: NCT03108430

Intervention type: OTHER
Intervention: Risk factors and incidence of IP after inhalation
Description: Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.

Intervention type: OTHER
Intervention: Risk factors and incidence of IP after inhalation
Description: Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.

Intervention type: OTHER
Intervention: Risk factors and incidence of IP after inhalation
Description: Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.
Study: NCT01260883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine 1 mg/kg
Description: Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac Tromethamine 0.5 mg/kg
Description: Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
Study: NCT02751294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine Control
Description: It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine dissolution profile X
Description: It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine and will be intermediate aged TQ Product.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine SIL
Description: It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafenoquine SIL
Description: It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.
Study: NCT02499809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recovery mode
Description: After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recovery mode
Description: After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).
Study: NCT01480258

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PR5I
Description: DTaP-HB-IPV-Hib (Diphtheria, tetanus, pertussis \[acellular, component\], hepatitis B \[recombinant DNA\], polio virus \[inactivated\], and Haemophilus influenza type b conjugate vaccine \[adsorbed\]) Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. PR5I is a liquid suspension hexavalent vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotavirus vaccine
Description: Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine
Description: Rotarix™ 1.5 mL oral dose at 2 and 4 months of age (subset 1, Italy and Sweden) or RotaTeq™ 2 mL oral dose at 2, 4 and 5 months of age (subset 2, Finland)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13™
Description: Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar 13™
Description: Prevenar 13™ 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: INFANRIX™ hexa
Description: Combined Diphtheria-Tetanus-acellular Pertussis \[DTaP\], Hepatitis B \[HepB\], Poliovirus \[IPV\] and Haemophilus influenzae type b \[Hib\] Vaccine 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age. Injection is to be administered in the upper anterolateral thigh, separate limb from the concomitant vaccine. INFANRIX™ hexa is provided as 2 components (lyophilized Hib and liquid DTaP, IPV, and HepB). Prior to administration, the vaccine must be reconstituted by adding the liquid DTaP-HepB-IPV component to the vial containing the Hib pellet.
Study: NCT04240197

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CompuFlo
Description: The occurrence of epidural pulse waves with CompuFlo and with standard pressure trnsducer

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CompuFlo
Description: The occurrence of epidural pulse waves with CompuFlo and with standard pressure trnsducer
Study: NCT04338568

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound
Description: The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound
Description: The lung ultrasound examination consists of two-sided scanning of the anterior and lateral chest wall and is performed with patients in supine or near-to-supine position.
Study: NCT02467465

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy modalities
Description: Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
Study: NCT01353521

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced ultrasound
Description: A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
Study: NCT01690000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 1 or 3 mg of melatonin PO each night for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 1 or 3 mg of melatonin PO each night for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 1 or 3 mg of melatonin PO each night for 12 months
Study: NCT03674788

Intervention type: DEVICE
Intervention: Transcatheter valve intervention

Intervention type: DEVICE
Intervention: Transcatheter valve intervention

Intervention type: DEVICE
Intervention: Transcatheter valve intervention
Study: NCT00635635

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided Imagery Audio
Description: Guided Imagery Audio listened to 5x per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music Audio
Description: Music only audio to be listened to 5x per week
Study: NCT01305044

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Classes
Description: The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
Study: NCT03441256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LION procedure
Description: Laparoscopic implantation of an impulse generator and four leads for electrical stimulation of femoral and sciatic nerves.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NMES
Description: Conventional neuromuscular electrical stimulation via surface electrodes.
Study: NCT02730091

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole 2.5 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: anastrozole 1 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: anastrozole 1 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: 50 mg three times a week (Monday Wednesday and Friday)
Study: NCT01124552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001 Botulinum toxin type A (Dose A)
Description: RT001 Botulinum Toxin Type A (Dose A)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RT001 Botulinum Toxin Type A (Dose B)
Description: RT001 Botulinum Toxin Type A (Dose B)

Intervention type: OTHER
Group type: OTHER
Intervention: Vehicle
Description: Vehicle Control
Study: NCT01545089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mattress protector for days 1 and 2
Description: A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mattress protector for days 3 and 4
Description: A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
Study: NCT01447043

Intervention type: DRUG
Intervention: Ranibizumab
Description: Patients with wet AMD treated with ranibizumab as prescribed by physician
Study: NCT01124552

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT02102698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ecopipam
Description: Ecopipam is a selective antagonist of the dopamine D1 receptor family.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ecopipam
Description: Ecopipam is a selective antagonist of the dopamine D1 receptor family.
Study: NCT00626327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM + MMRV
Description: One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MMRV
Description: one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM
Description: Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
Study: NCT02160743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)
Study: NCT00391443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan
Description: Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight \> 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight \< 40 kg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
Study: NCT01427855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat red meat diet
Description: 4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat non-meat diet
Description: 4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
Study: NCT02467465

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Invasive Physical therapy modalities
Description: Dry needling added to massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
Study: NCT01427855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High saturated fat white meat diet
Description: 4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low saturated fat red meat diet
Description: 4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low saturated fat white meat diet
Description: 4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low saturated fat non meat diet
Description: 4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
Study: NCT04328467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine; 200mg tablet; oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine; 200mg tablet; oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; tablet; oral
Study: NCT00330499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Weekly Cisplatin 35mg/m2 x 6 doses, IV administration

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation treatment
Description: 64Gy reference dose in 32 fractions over 6.5 weeks
Study: NCT00892879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy surgery
Description: Single port laparoscopic cholecystectomy surgery versus a standard four port device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic cholecystectomy surgery
Description: Single port laparoscopic cholecystectomy surgery versus a standard four port device.
Study: NCT00330499

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation treatment
Description: 64Gy reference dose in 32 fractions over 6.5 weeks
Study: NCT02593552

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DriveCam
Description: Video event monitoring device
Study: NCT03284164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Exalidex (TXL)
Description: Drug: Tenofovir Exalidex (TXL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Exalidex (TXL)
Description: Drug: Tenofovir Exalidex (TXL)
Study: NCT00546156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Standard chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Standard chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Standard chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Standard chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Standard chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Standard chemotherapy regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
Study: NCT04078217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jintronix
Description: Participants will perform an exercise program at home through a telerehabilitation platform called Jintronix.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet
Description: Home-based exercise program using a paper booklet (not the technology).
Study: NCT01333709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction trichemotherapy - FOLFIRINOX regimen
Description: A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).

Intervention type: DRUG
Group type: OTHER
Intervention: Induction trichemotherapy - FOLFIRINOX regimen
Description: A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
Study: NCT03747874

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ventilatory polygraphy
Description: we put a ventilatory polygraphy device on the patient in the evening, they come back home to sleep while the device is recording ventilatory parameters and they come back the morrow to give the device back
Study: NCT00196560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immobilization in External Rotation
Study: NCT05048810

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA-NT-20.3
Description: In this study, all patients will receive one injection of 68Ga-DOTA-NT-20.3, a PET radiopharmaceutical selective for neurotensin receptor 1 (NTR-1). For the injection, subjects will receive a target dose of 2-4 MBq per kg of body weight as a bolus injection. 68Ga-DOTA-NT-20.3 injection will be followed by a 10 ml saline flush.